BRPI0820793A2 - Seprase como marcador de câncer - Google Patents

Seprase como marcador de câncer

Info

Publication number
BRPI0820793A2
BRPI0820793A2 BRPI0820793-3A BRPI0820793A BRPI0820793A2 BR PI0820793 A2 BRPI0820793 A2 BR PI0820793A2 BR PI0820793 A BRPI0820793 A BR PI0820793A BR PI0820793 A2 BRPI0820793 A2 BR PI0820793A2
Authority
BR
Brazil
Prior art keywords
cancer
seprase
types
assessment
specific
Prior art date
Application number
BRPI0820793-3A
Other languages
English (en)
Inventor
Wolfgang Rollinger
Johann Karl
Jarema Peter Kochan
Markus Roessler
Michael Tacke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07023897A external-priority patent/EP2071337A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0820793A2 publication Critical patent/BRPI0820793A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96411—Serine endopeptidases (3.4.21)
BRPI0820793-3A 2007-12-10 2008-12-08 Seprase como marcador de câncer BRPI0820793A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07023897A EP2071337A1 (en) 2007-12-10 2007-12-10 Seprase as a marker for cancer
EP08015310 2008-08-29
PCT/EP2008/010385 WO2009074275A1 (en) 2007-12-10 2008-12-08 Seprase as a marker for cancer

Publications (1)

Publication Number Publication Date
BRPI0820793A2 true BRPI0820793A2 (pt) 2015-06-16

Family

ID=40373548

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820793-3A BRPI0820793A2 (pt) 2007-12-10 2008-12-08 Seprase como marcador de câncer

Country Status (15)

Country Link
US (1) US8980573B2 (pt)
EP (1) EP2223115B1 (pt)
JP (1) JP5563988B2 (pt)
KR (1) KR101202220B1 (pt)
CN (1) CN101896818B (pt)
AT (1) ATE524740T1 (pt)
AU (1) AU2008335855B2 (pt)
BR (1) BRPI0820793A2 (pt)
CA (1) CA2706115A1 (pt)
DK (1) DK2223115T3 (pt)
ES (1) ES2372442T3 (pt)
HK (1) HK1150884A1 (pt)
MX (1) MX2010004671A (pt)
PL (1) PL2223115T3 (pt)
WO (1) WO2009074275A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8213005B2 (en) 2003-07-22 2012-07-03 King Saud University Method for discriminating between benign and malignant prostate tumors
CA2728153C (en) * 2008-07-03 2015-01-27 F. Hoffmann-La Roche Ag Asc as a marker for lung cancer
MX342967B (es) 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
JP2013519095A (ja) 2010-02-05 2013-05-23 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
US20130225442A1 (en) * 2010-10-20 2013-08-29 Rush University Medical Center Lung Cancer Tests
EP2684049A1 (en) * 2011-03-11 2014-01-15 Roche Diagniostics GmbH Seprase as marker for chronic obstructive pulmonary disease (copd)
ES2578477T3 (es) 2011-03-11 2016-07-27 Roche Diagniostics Gmbh ASC como marcador de la enfermedad pulmonar obstructiva crónica (EPOC)
CN102435748B (zh) * 2011-11-25 2014-07-16 广东药学院 一种双抗夹心酶联免疫检测试剂盒及其制备方法
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
JP6352909B2 (ja) 2012-06-27 2018-07-04 バーグ エルエルシー 前立腺癌の診断および処置におけるマーカーの使用
CA2891028C (en) 2012-11-09 2017-02-07 F. Hoffmann-La Roche Ag In vitro capture and analysis of circulating tumor cells
SG11201504241QA (en) * 2012-11-30 2015-06-29 Applied Proteomics Inc Method for evaluation of presence of or risk of colon tumors
AU2014207509B2 (en) 2013-01-17 2019-12-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9753037B2 (en) 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
KR101619122B1 (ko) 2013-08-14 2016-05-10 연세대학교 산학협력단 탈메틸화 의존적 ａｓｃ 발현을 촉진시켜서 대장암 종양세포의 사멸감수성을 증진시키는 항암제 병용 투여용 후보물질의 스크리닝 방법
EP3080299B1 (en) 2013-12-09 2020-09-30 Rush University Medical Center Biomarkers of rapid progression in advanced non-small cell lung cancer
PL230661B1 (pl) * 2014-01-29 2018-11-30 Centrum Onkologii Inst Im Marii Sklodowskiej Curie Oddzial W Gliwicach Metoda predykcyjna in vitro do przewidywania i/lub wykluczenia obecnosci raka pluc, zastosowanie in vitro metody predykcyjnej oraz zestaw testowy do wykrywania in vitro raka pluc
EP2916134B1 (en) * 2014-03-05 2017-08-16 Roche Diagnostics GmbH Use of Seprase for differential diagnosis of acute dyspnea
CA2970143A1 (en) 2014-12-08 2016-06-16 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2016146174A1 (en) * 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
US9689874B2 (en) 2015-04-10 2017-06-27 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
WO2018020530A1 (ja) * 2016-07-25 2018-02-01 静岡県 肝外胆管癌、肝内胆管癌、又は胆嚢癌の診断用バイオマーカー
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
DE102017010455A1 (de) * 2017-06-13 2018-12-13 Forschungszentrum Jülich GmbH Verfahren zum Nachweis von Aggregaten biotherapeutischer Substanzen in einer Probe
US20210231669A1 (en) * 2017-09-05 2021-07-29 Oncotag Diagnotics Co., LTD Method for diagnosing pancreatic cancer using methionyl-trna synthetase, and pancreatic cancer diagnostic kit using same
CN112540176B (zh) * 2020-07-08 2021-09-28 深圳霁因生物医药转化研究院 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
WO2005043121A2 (en) 2003-10-31 2005-05-12 Vitatex, Inc. Blood test prototypes and methods for the detection of circulating tumor and endothelial cells
EP1799717B1 (en) * 2004-10-22 2015-05-20 Danisco US Inc. Isolating human antibodies
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
CN101379069A (zh) * 2005-12-19 2009-03-04 塔夫茨大学信托人 软蛋白酶抑制剂及其前软形式

Also Published As

Publication number Publication date
AU2008335855B2 (en) 2012-08-30
DK2223115T3 (da) 2011-12-12
KR20100091212A (ko) 2010-08-18
AU2008335855A1 (en) 2009-06-18
EP2223115B1 (en) 2011-09-14
CN101896818A (zh) 2010-11-24
ATE524740T1 (de) 2011-09-15
WO2009074275A1 (en) 2009-06-18
KR101202220B1 (ko) 2012-11-16
HK1150884A1 (zh) 2012-01-13
ES2372442T3 (es) 2012-01-19
MX2010004671A (es) 2010-05-27
PL2223115T3 (pl) 2012-02-29
CA2706115A1 (en) 2009-06-18
JP2011506941A (ja) 2011-03-03
US8980573B2 (en) 2015-03-17
US20100240081A1 (en) 2010-09-23
EP2223115A1 (en) 2010-09-01
JP5563988B2 (ja) 2014-07-30
CN101896818B (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
BRPI0820793A2 (pt) Seprase como marcador de câncer
WO2010072383A8 (en) Armet as a marker for cancer
ES2505466T3 (es) Procedimientos para predecir la respuesta al tratamiento del cáncer de mama triple negativo
ATE554389T1 (de) Apex als marker für lungenkrebs
DE602006018578D1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
ES2683362T3 (es) Microvesículas obtenidas a partir de células tumorales
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
WO2010118166A3 (en) Methods of predicting cancer risk using gene expression in premalignant tissue
JP2011521618A5 (pt)
WO2010097186A8 (en) Use of s-erbb-3 as a marker for cancer
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
JP2006311860A5 (pt)
ATE551073T1 (de) Markierte hgf-bindende peptide für bildgebung
FI2398902T3 (fi) Menetelmiä ja koostumuksia syövän diagnoosia ja hoitoa varten
WO2011015602A3 (en) Lung cancer biomarkers
WO2010051314A3 (en) Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations
EA201490946A1 (ru) Способ количественной оценки лечения рака
WO2005001092A3 (en) Compositions and methods for diagnosing and treating cancers
WO2012071096A3 (en) Arid1a and ppp2r1a mutations in cancer
PL2021794T3 (pl) Zastosowanie białka S100A 12 jako markera raka okrężnicy i odbytnicy
WO2009015294A8 (en) Biomarkers for human papillomavirus-associated cancers
WO2020012367A3 (en) Dna methylation markers for noninvasive detection of cancer and uses thereof
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
WO2007106425A3 (en) Biomarkers of the dysplastic state of cells

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]